NASDAQ:NYMXNymox Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nymox Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.95 +0.24 (+6.47 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$3.68Now: $3.95▼$3.9550-Day Range$2.20MA: $3.01▼$3.4652-Week Range$1.32Now: $3.95▼$4.09Volume275,497 shsAverage Volume191,681 shsMarket Capitalization$281.32 millionP/E RatioN/ADividend YieldN/ABeta1.73 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nymox Pharmaceutical. Previous Next 2.4 Community Rank Outperform VotesNymox Pharmaceutical has received 147 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNymox Pharmaceutical has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentNymox Pharmaceutical has received 51.16% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote “Outperform” if you believe NYMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNymox Pharmaceutical does not currently pay a dividend.Dividend GrowthNymox Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nymox Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders54.00% of the stock of Nymox Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.97% of the stock of Nymox Pharmaceutical is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nymox Pharmaceutical is -19.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nymox Pharmaceutical is -19.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNymox Pharmaceutical has a P/B Ratio of 79.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.68 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NYMX Previous Symbol CUSIPN/A CIK1018735 Webwww.nymox.com Phone800-936-9669Debt Debt-to-Equity Ratio0.09 Current Ratio1.74 Quick Ratio1.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales2,344.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book79.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,160,000.00 Net Margins-14,341.11% Return on Equity-285.17% Return on Assets-199.82%Miscellaneous EmployeesN/A Outstanding Shares71,219,000Market Cap$281.32 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable NASDAQ:NYMX Rates by TradingView Receive NYMX News and Ratings via Email Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter. Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions How has Nymox Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NYMX shares have increased by 72.5% and is now trading at $3.95. View which stocks have been most impacted by Coronavirus. When is Nymox Pharmaceutical's next earnings date? Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Nymox Pharmaceutical. How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Corp (NASDAQ:NYMX) released its quarterly earnings results on Monday, March, 30th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The biopharmaceutical company earned $0.03 million during the quarter. Nymox Pharmaceutical had a negative return on equity of 285.17% and a negative net margin of 14,341.11%. View Nymox Pharmaceutical's earnings history. Has Nymox Pharmaceutical been receiving favorable news coverage? Headlines about NYMX stock have trended extremely negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nymox Pharmaceutical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news aboutNymox Pharmaceutical. Are investors shorting Nymox Pharmaceutical? Nymox Pharmaceutical saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,270,000 shares, an increase of 7.9% from the April 30th total of 3,030,000 shares. Based on an average daily volume of 153,200 shares, the short-interest ratio is currently 21.3 days. Approximately 8.3% of the shares of the stock are sold short. View Nymox Pharmaceutical's Current Options Chain. Who are some of Nymox Pharmaceutical's key competitors? Some companies that are related to Nymox Pharmaceutical include Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO) and BG Medicine (BGMD). View all competitors. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), Synergy Pharmaceuticals (SGYP), Catalyst Pharmaceuticals (CPRX), TherapeuticsMD (TXMD), MEI Pharma (MEIP) and Rigel Pharmaceuticals (RIGL). Who are Nymox Pharmaceutical's key executives? Nymox Pharmaceutical's management team includes the following people: Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)Mr. Erik Danielsen, Chief Financial Officer (Age 56)Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55) What is Nymox Pharmaceutical's stock symbol? Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX." Who are Nymox Pharmaceutical's major shareholders? Nymox Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.16%), Patriot Financial Group Insurance Agency LLC (0.10%), First Citizens Financial Corp (0.05%), Wedbush Securities Inc. (0.05%), Private Advisor Group LLC (0.04%) and Deutsche Bank AG (0.04%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View institutional ownership trends for Nymox Pharmaceutical. Which major investors are selling Nymox Pharmaceutical stock? NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Nymox Pharmaceutical. Which major investors are buying Nymox Pharmaceutical stock? NYMX stock was bought by a variety of institutional investors in the last quarter, including First Citizens Financial Corp, Patriot Financial Group Insurance Agency LLC, Citigroup Inc., Jane Street Group LLC, WMS Partners LLC, Creative Planning, Deutsche Bank AG, and Paloma Partners Management Co. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson, and Randall J Lanham. View insider buying and selling activity for Nymox Pharmaceutical. How do I buy shares of Nymox Pharmaceutical? Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nymox Pharmaceutical's stock price today? One share of NYMX stock can currently be purchased for approximately $3.95. How big of a company is Nymox Pharmaceutical? Nymox Pharmaceutical has a market capitalization of $281.32 million and generates $120,000.00 in revenue each year. What is Nymox Pharmaceutical's official website? The official website for Nymox Pharmaceutical is www.nymox.com. How can I contact Nymox Pharmaceutical? Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
